Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebo-controlled study

American Journal of Psychiatry

Volumn 159, Issue 11, 2002, Pages 1896-1901

  Michelson, David ^a   Allen, Albert J ^a   Busner, Joan ^a   Casat, Charles ^a   Dunn, David ^a   Kratochvil, Christopher ^a   Newcorn, Jeffrey ^a   Sallee, F Randy ^a   Sangal, R Bart ^a   Saylor, Keith ^a   West, Scott ^a   Kelsey, Douglas ^a   Wernicke, Joachim ^a   Trapp, Nancy J ^a   Harder, Donald ^a  

^a ELI LILLY AND COMPANY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ATOMOXETINE; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADOLESCENT; ANOREXIA; ARTICLE; ASTHENIA; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; DYSPEPSIA; FEMALE; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; INJURY; MAJOR CLINICAL STUDY; MALE; MENTAL INSTABILITY; MULTICENTER STUDY; NAUSEA; OUTCOMES RESEARCH; PARENT; PHARYNGITIS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RASH; RHINITIS; SOMNOLENCE; TEACHER; VERTIGO; VOMITING;

ADOLESCENT; ANTIDEPRESSIVE AGENTS; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CHILD; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; PERSONALITY ASSESSMENT; PROPYLAMINES; TREATMENT OUTCOME;

EID: 0036842531     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.159.11.1896     Document Type: Article

References (17)

1. Wilens TE: The stimulants revisited. Child Adolesc Psychiatr Clin N Am 2000; 9:573-603
2. Biederman J, Baldessarini RJ, Wright V, Knee D, Harmatz JS: A double-blind placebo controlled study of desipramine in the treatment of ADD, I: Efficacy. J Am Acad Child Adolesc Psychiatry 1989; 28:777-784
3. Conners CK, Casat CD, Gualtieri CT, Weller E, Reader M, Reiss A, Weller RA, Khayrallah M, Ascher J: Bupropion hydrochloride in attention deficit disorder with hyperactivity. J Am Acad Child Adolesc Psychiatry 1996; 35:1314-1321
4. Heiligenstein J, Spencer T, Faries DE, Biederman J, Kratochvil CJ, Conners CK: Efficacy of atomoxetine vs placebo in pediatric outpatients with ADHD, in Proceedings of the 47th Annual Meeting of the American Academy of Child and Adolescent Psychiatry. Washington, DC, AACAP, 2000
5. Michelson D, Faries DE, Wernicke J, Kelsey DK, Kendrick KL, Sallee FR, Spencer T (Atomoxetine ADHD Study Group): Atomoxetine in the treatment of children and adolescents with ADHD: A randomized, placebo-controlled dose-response study. Pediatrics 2001; 108:e83
6. Spencer T, Biederman J, Wilens T, Prince J, Hatch M, Jones J, Harding M, Faraone SV, Seidman L: Effectiveness and tolerability of tomoxetine in adults with attention deficit hyperactivity disorder. Am J Psychiatry 1998; 155:693-695
7. Kaufman J, Birmaher B, Brent D, Rao U, Ryan N: Kiddie-SADS - Present and Lifetime Version (K-SADS-PL), Version 1.0 of October 1996 Ed. Pittsburgh, University of Pittsburgh School of Medicine, Department of Psychiatry, 1996
8. DuPaul GJ, Power TJ, Anastopoulos AD, Reid R: ADHD Rating Scale-IV: Checklists, Norms, and Clinical Interpretations. New York, Guilford, 1998
9. Faries DE, Yalcin I, Harder D, Heiligenstein JH: Validation of the ADHD Rating Scale as a clinician administered and scored instrument. J Atten Disord 2001; 5:39-47
10. Conners CK, Sitarenios G, Parker JD, Epstein JN: The revised Conners' Parent Rating Scale (CPRS-R): Factor structure, reliability, and criterion validity. J Abnorm Child Psychol 1998; 26: 257-268
11. Conners CK, Sitarenios G, Parker JD, Epstein JN: Revision and restandardization of the Conners Teacher Rating Scale (CTRS-R): Factor structure, reliability, and criterion validity. J Abnorm Child Psychol 1998; 26:279-291
12. Guy W (ed): ECDEU Assessment Manual for Psychopharmacology: Publication ADM 76-338. Washington, DC, US Department of Health, Education, and Welfare, 1976, pp 218-222
13. SAS/STAT Software: Changes and Enhancements Through Release 6.12, Cary, NC, SAS Institute, 1997
14. Jacobson NS, Truax P: Clinical significance: A statistical approach to defining meaningful change in psychotherapy research. J Consult Clin Psychol 1991; 59:12-19
15. Spencer T, Biederman J, Heiligenstein J, Wilens T, Faries D, Prince J, Faraone SV, Rea J, Witcher J, Zeras S: An open-label, dose-ranging study of atomoxetine in children with attention deficit hyperactivity disorder. J Child Adolesc Psychopharmacol 2001; 11:251-265
16. Greenhill LL, Swanson JM, Vitiello B, Davies M, Clevenger W, Wu M, Arnold LE, Abikoff HB, Bukstein OG, Conners CK, Elliott GR, Hechtman L, Hinshaw SP, Hoza B, Jensen PS, Kraemer HC, March JS, Newcorn JH, Severe JB, Wells K, Wigal T: Impairment and deportment responses to different methylphenidate doses in children with ADHD: The MTA titration trial. J Am Acad Child Adolesc Psychiatry 2001; 40:180-187
17. Schachter HM, Pham B, King J, Langford S, Moher D: How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. Can Med Assoc J 2001; 165:1475-1488